November 28th 2015
The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.
November 26th 2015
A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.
November 21st 2015
Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
November 7th 2015
With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.
November 6th 2015
Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.
November 4th 2015
Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.
October 24th 2015
Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.
October 13th 2015
The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.
October 12th 2015
Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.
September 20th 2015
With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.
August 11th 2015
In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.
August 10th 2015
Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.
August 6th 2015
New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.
August 5th 2015
Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.
August 4th 2015
Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.
July 29th 2015
Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.
July 27th 2015
Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.
June 10th 2015
There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.
June 7th 2015
Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.
June 5th 2015
Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.